Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian M Sadler

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Journal of Clinical Pharmacology|February 3, 2018
Oliceridine, a Novel G Protein-Biased Ligand at the μ-Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. II: Simulation of Potential Phase 3 Study Designs Using a Pharmacokinetic/Pharmacodynamic ModelMichael J Fossler, Brian M Sadler, Colm Farrell, et al.
British Journal of Clinical Pharmacology|March 31, 2015
Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patientsJianping Zhang, Siobhán Hayes, Brian M Sadler, et al.
Clinical Pharmacokinetics|August 24, 2007
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteersYan-Ling He, Brian M Sadler, Ron Sabo, et al.
Pain|June 24, 2014
Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteersDavid G Soergel, Ruth Ann Subach, Nancy Burnham, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2016
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529Ishani Landry, Li Zhu, Malaz Abu Tarif, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 15, 2017
Crowdsourced Asparagus Urinary Odor Population KineticsAnuradha Ramamoorthy, Brian M Sadler, J G Coen van Hasselt, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Journal of Clinical Pharmacology|February 3, 2018
Oliceridine, a Novel G Protein-Biased Ligand at the μ-Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. II: Simulation of Potential Phase 3 Study Designs Using a Pharmacokinetic/Pharmacodynamic ModelMichael J Fossler, Brian M Sadler, Colm Farrell, et al.
British Journal of Clinical Pharmacology|March 31, 2015
Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patientsJianping Zhang, Siobhán Hayes, Brian M Sadler, et al.
Clinical Pharmacokinetics|August 24, 2007
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteersYan-Ling He, Brian M Sadler, Ron Sabo, et al.
Pain|June 24, 2014
Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteersDavid G Soergel, Ruth Ann Subach, Nancy Burnham, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2016
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529Ishani Landry, Li Zhu, Malaz Abu Tarif, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 15, 2017
Crowdsourced Asparagus Urinary Odor Population KineticsAnuradha Ramamoorthy, Brian M Sadler, J G Coen van Hasselt, et al.
Pageof 3